Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 Return-on-Tangible-Asset is 1.76% as of Dec. 2025. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,996 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 85.47% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Star Combo Pharma's annualizedNet Income for the quarter that ended in Dec. 2025 was A$0.83 Mil. Star Combo Pharma's average total tangible assets for the quarter that ended in Dec. 2025 was A$47.05 Mil. Therefore, Star Combo Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 1.76%.
The historical rank and industry rank for Star Combo Pharma's Return-on-Tangible-Asset or its related term are showing as below:
ASX:S66'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -16.01 Med: -5.48 Max: 11.81
Current: 11.81
During the past 9 years, Star Combo Pharma's highest Return-on-Tangible-Asset was 11.81%. The lowest was -16.01%. And the median was -5.48%.
ASX:S66's Return-on-Tangible-Asset is ranked better than 85.47% of 1996
companies
in the Consumer Packaged Goods industry
Industry Median: 3.5
vs ASX:S66: 11.81
Star Combo Pharma (ASX:S66) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Star Combo Pharma Return-on-Tangible-Asset Related Terms
Star Combo Pharma Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:S66 vs PG, CL, KVUE: Return-on-Tangible-Asset Comparison
For the Household & Personal Products subindustry, Star Combo Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 1.76% mean?
Star Combo Pharma (ASX:S66) has a Return-on-Tangible-Asset of 1.76% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #290 out of 1996 companies in the Consumer Packaged Goods industry, placing it in the top 14.5%.
Is Star Combo Pharma's Return-on-Tangible-Asset too high?
Star Combo Pharma's current Return-on-Tangible-Asset is 1.76%. The Consumer Packaged Goods industry median Return-on-Tangible-Asset is 3.50. Star Combo Pharma's value of 1.76% is 49.7% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #290 out of 1996 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Return-on-Tangible-Asset compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #290 out of 1996 companies for Return-on-Tangible-Asset. This places Star Combo Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.50. Star Combo Pharma's value of 1.76% is 49.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.50, based on 1,996 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Return-on-Tangible-Asset of 1.76% is 49.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Return-on-Tangible-Asset is 1.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current Return-on-Tangible-Asset is 1.76% and 49.7% below the Consumer Packaged Goods industry median of 3.50. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Return-on-Tangible-Asset is 1.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Return-on-Tangible-Asset: 1.76%
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 49.7% below the Consumer Packaged Goods median (#290 of 1996)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
